Sector News

Fosun Pharma buys smaller stake in Gland Pharma for $1.1 billion

September 18, 2017
Life sciences

Shanghai Fosun Pharmaceutical Group is trimming the size of the stake it will buy in India’s Gland Pharma to 74 percent for $1.1 billion, in a bid to salvage the stalled deal that would be the biggest takeover by a Chinese firm in India.

Fosun Pharma had struck a deal in July last year to buy an 86 percent stake valued at about $1.26 billion in the Indian generic injectable drugmaker, but the deal had raised concerns among some in the Indian government, a source had told Reuters previously.

India allows foreign investment of up to 100 percent in its pharmaceutical sector but above 74 percent requires government approval.

Two sources with knowledge of the matter told Reuters that the Chinese drugmaker had agreed to lower the stake it planned to acquire in Gland to 74 percent, mainly because it sought to get the deal completed more smoothly and faster. Gland is backed by private equity firm KKR & Co LP .

Fosun said in a statement on Sunday the deal no longer required a nod from India’s Cabinet Committee on Economic Affairs, chaired by Prime Minister Narendra Modi. It said it had already received approval from Chinese regulators and applied for antitrust approval in the United States and India.

The Chinese drugmaker added that Gland Pharma’s founding family wanted to retain a bigger holding in the Indian company because of its good performance.

Gland managing director Ravi Penmetsa told Reuters some approvals the original deal had received were at risk of expiring.

“Now with this new agreement, we won’t have to reapply for those,” he said, adding that he expects the deal to be completed in two weeks.

Fosun Pharma’s parent, Fosun International (0656.HK), has been the poster child for China’s decade-long overseas push that saw Chinese bidders spend a record $105 billion on assets ranging from film studios to football clubs in 2016.

Best known outside China for its acquisition of French resort chain Club Med, Fosun International was among acquisitive firms that found itself in the cross-hairs of Chinese authorities, sources have said.

But its executives said in late August that Fosun would continue to conduct overseas deals and scout for targets in areas including drug manufacturing.

Fosun Pharma said in mid-August it was bidding for a stake in U.S. specialty drugmaker Arbor Pharmaceuticals LLC.

On Sunday Fosun Pharma said it would spend no more than $25 million to market the Indian company’s enoxaparin blood-thinning drug in the United States, when it obtains approval there, cutting the previously proposed marketing spend by half.

In a statement on Sunday, Gland said the deal would allow it to make biosimilars – lucrative copies of biotech drugs – at Fosun’s site and sell them in India.

“It won’t happen overnight, but we have started working on it,” Penmetsa said.

Penmetsa and his father, P.V.N. Raju, will remain on the Gland board and the current management team will continue to run the company.

By Dominique Patton and Zeba Siddiqui

Source: Reuters

Related News

March 6, 2021

Takeda takes full control of drug for rare epilepsies

Life sciences

The deal inked with New York-based Ovid Therapeutics carries an almost $200 million upfront payment and could be worth as much as $856 million provided the medicine, known as soticlestat, hits certain milestones. 

March 6, 2021

Novartis signs Covid-19 vaccine manufacturing agreement with CureVac

Life sciences

Novartis has entered an initial agreement to manufacture the mRNA and bulk drug product for CureVac’s Covid-19 vaccine candidate, CVnCoV.

March 6, 2021

Disney teams with Philips to bring its characters to pediatric imaging

Life sciences

A whole new world: Philips and the Walt Disney Company will use animated shorts featuring some of Disney’s most famous characters in customized stories created with clinical guidance from Philips.

Send this to a friend